Table 2.

Current clinical trials of B-Raf and/or MEK inhibitors in different grade BRAF-mutated gliomas.

STUDY PHASE AND PURPOSE	RECRUITMENT STATUS	TREATMENT	DISEASE
PHASE I STUDY	Active, not recruiting	Vemurafenib	▪ Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
PHASE I STUDY	Recruiting	ABM-1310 Cobimetinib	▪ Advanced Solid Tumor ▪ BRAF V600 Mutation
Safety of ABM-1310 in Patients With Advanced Solid Tumors
PHA SE I, II STUDY	Recruiting	Dabrafenib	▪ Low Grade Glioma (LGG) of Brain With BRAF Aberration ▪ High Grade Glioma (HGG) of the Brain With BRAF Aberration ▪ Low Grade Glioma of Brain With Neurofibromatosis Type 1
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration		Trametinib
		Hydroxychloroquine
PHASE I, II STUDY	Completed	Trametinib	▪ Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations		Dabrafenib
PHASE I, II STUDY	Active, not recruiting	Selumetinib	▪ Low Grade Glioma ▪ Recurrent Childhood Pilocytic Astrocytoma ▪ Recurrent Neurofibromatosis Type 1 ▪ Recurrent Visual Pathway Glioma ▪ Refractory Neurofibromatosis Type 1 ▪ Refractory Visual Pathway Glioma
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
PHASE II STUDY	Recruiting	Encorafenib	▪ High Grade Glioma ▪ BRAF V600E ▪ BRAF V600K ▪ Anaplastic Astrocytoma ▪ Anaplastic Pleomorphic Xanthoastrocytoma ▪ Gliosarcoma ▪ Glioblastoma
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)		Binimetinib
PHASE II STUDY	Recruiting	Dabrafenib Mesylate	▪ Anaplastic Astrocytoma ▪ Anaplastic Ganglioglioma ▪ Anaplastic Pleomorphic Xanthoastrocytoma ▪ Glioblastoma ▪ Malignant Glioma ▪ WHO Grade III Glioma
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma		Radiation Therapy
		Trametinib Dimethyl Sulfoxide
PHASE II STUDY	Recruiting	Trametinib	▪ Low-grade Glioma ▪ Plexiform Neurofibroma ▪ Central Nervous System Glioma
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway
PHASE II STUDY	Recruiting	Vemurafenib	▪ Advanced Malignant Solid Neoplasm ▪ Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma ▪ Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma ▪ Ependymoma ▪ Ewing Sarcoma ▪ Hepatoblastoma ▪ Langerhans Cell Histiocytosis ▪ Malignant Germ Cell Tumor ▪ Malignant Glioma ▪ Osteosarcoma ▪ Peripheral Primitive Neuroectodermal Tumor ▪ Recurrent Childhood Central Nervous System Neoplasm ▪ Recurrent Childhood Non-Hodgkin Lymphoma ▪ Recurrent Malignant Solid Neoplasm ▪ Recurrent Neuroblastoma ▪ Refractory Malignant Solid Neoplasm ▪ Refractory Neuroblastoma ▪ Refractory Non-Hodgkin Lymphoma ▪ Refractory Primary Central Nervous System Neoplasm ▪ Rhabdoid Tumor ▪ Rhabdomyosarcoma ▪ Soft Tissue Sarcoma ▪ Wilms Tumor
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
PHASE II STUDY	Active, not recruiting	Dabrafenib Trametinib Carboplatin with vincristine	▪ Diffuse Astrocytoma ▪ Anaplastic Astrocytoma ▪ Astrocytoma ▪ Oligodendroglioma, Childhood ▪ Anaplastic Oligodendroglioma ▪ Glioblastoma ▪ Pilocytic Astrocytoma ▪ Giant Cell Astrocytoma ▪ Pleomorphic Xanthoastrocytoma ▪ Anaplastic Pleomorphic Xanthoastrocytoma ▪ Angiocentric Glioma ▪ Chordoid Glioma of Third Ventricle ▪ Gangliocytoma ▪ Ganglioglioma ▪ Anaplastic Ganglioglioma ▪ Dysplastic Gangliocytoma of Cerebrellum ▪ Desmoplastic Infantile Astrocytoma and Ganglioglioma ▪ Papillary Glioneuronal Tumor ▪ Rosette-forming Glioneurona Tumor ▪ Central Neurocytoma ▪ Extraventricular Neurocytoma ▪ Cerebellar Iponeurocytoma
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
PHASE IV STUDY	Recruiting	Dabrafenib	▪ Melanoma ▪ Non-Small Cell Lung Cancer ▪ Solid Tumor ▪ Rare Cancers ▪ High Grade Glioma
Dabrafenib and/or Trametinib Rollover Study		Trametinib

HGG, high-grade gliomas; LGG, low-grade gliomas.